Healthcare occupational exposure to blood or other body fluids: Difference between revisions

m (Rossdonaldson1 moved page Occupational Exposure to Occupational exposure)
(44 intermediate revisions by 7 users not shown)
Line 1: Line 1:
==HIV==
==Background==
*[[HIV Prophylaxis (Non-Occupational)]]
*The majority of persons (e.g. source patients) chronically infected with hepatitis B and C (65% to 75%) are not aware of their infection <ref>[https://www.ncbi.nlm.nih.gov/pubmed/23740193 Fretz R, Negro F, Bruggmann P et al. Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Med Wkly. 2013 May 17;143:w13793.]</ref>
*[[HIV Prophylaxis (Occupational)]]


==Hep B==
==Clinical Features==
# risk of infc 2- 30% after needle stick
*Frequently from needlestick injuries or other occupational exposures to bodily fluids
# can survive on dried blood for 1 wk
# found in all fluids but highest conc in blood and therefore highest risk with blood
# hep b surface antibodies confers life long immunity
# don't need to test pt or source if pt certain fully/ successfully immunized- antibodies > 10 IU at some time
# if pt not successfully immunized, give hep b immune globulin
# failed 3 shots/ 1 series- give hep booster and immune globulin x 2 doses over 1 mo
# failed 6 shots/ 2 series- give sequential immune globulin


Patient Unvaccinated, Source Pos
==Differential Diagnosis==
--> HBIG + vaccine
*[[Laceration]]
*Retained [[foreign body]]


==Hep C==
==Evaluation==
# no prophylaxsis
''Most commonly, the only actionable lab on the day of exposure is a rapid [[HIV]] test from the source-patient (for consideration of [[PEP]])''
# no interferon, no antivirals, no globulin
===Source-patient labs===
# not xmitted efficiently through needle stick- 2% rate
*Rapid HIV
# get basline hcv test and ALT
*Consider [[hepatitis]] panel and possibly RPR
**Hepatitis B and C infectivity of source patient:
***HBs-Ag (active infection)
***HBc-Ab IgM (window period)
***HepC-Ab, plus or minus viral load


Post Exp Viral Hep Counseling
===Exposed-patient labs===
# can still breast feed
*In some systems, NO immediate laboratory testing is performed
# no organ/ blood donation
*In many systems, a standardized baseline lab panel is sent in the ED and then followed up at employee health the next day
# no worry about modifiying sex pattern or becoming preg
*If giving HIV [[PEP]]:
**Rapid [[HIV]] (to confirm they do not ''already'' have HIV)
**CBC, C7, LFTs, pregnancy test


==Management==
===[[HIV]]===
*Consider [[HIV post-exposure prophylaxis]]
{{HIV post-exposure prophylaxis regimens}}
===[[Hepatitis B]]===
*Not normally indicated, assuming patient has had full course of Hepatitis B vaccination (as all healthcare workers should have)
**If exposed-patient NOT already vaccinated, see [[Hepatitis_B#Hepatitis_B_Post-Exposure_Prophylaxis|Hepatitis B Post-Exposure Prophylaxis]]
===[[Hepatitis C]]===
*No prophylaxis regimen has any benefit
==Disposition==
*Outpatient management with employee health follow-up


==See Also==
==See Also==
*[[Harbor: Occupational Exposure]]
*[[HIV post-exposure prophylaxis]]
*www.needlestick.mednet.ucla.edu
 
==Source==
==References==
6/06 MISTRY
<references/>


[[Category:ID]]
[[Category:ID]]

Revision as of 22:35, 19 November 2017

Background

  • The majority of persons (e.g. source patients) chronically infected with hepatitis B and C (65% to 75%) are not aware of their infection [1]

Clinical Features

  • Frequently from needlestick injuries or other occupational exposures to bodily fluids

Differential Diagnosis

Evaluation

Most commonly, the only actionable lab on the day of exposure is a rapid HIV test from the source-patient (for consideration of PEP)

Source-patient labs

  • Rapid HIV
  • Consider hepatitis panel and possibly RPR
    • Hepatitis B and C infectivity of source patient:
      • HBs-Ag (active infection)
      • HBc-Ab IgM (window period)
      • HepC-Ab, plus or minus viral load

Exposed-patient labs

  • In some systems, NO immediate laboratory testing is performed
  • In many systems, a standardized baseline lab panel is sent in the ED and then followed up at employee health the next day
  • If giving HIV PEP:
    • Rapid HIV (to confirm they do not already have HIV)
    • CBC, C7, LFTs, pregnancy test

Management

HIV

Preferred HIV PEP Regimen[2][3]

PEP should be started as soon as possible after significant exposure and continued for 28 days[4]

  • Raltegravir (Isentress; RAL) 400 mg PO twice daily, plus
  • Truvada, 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)

Other Considerations

  • If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP
  • Consider interactions with current medication interactions and contraindications, such as renal impairment with Truvada
    • For patients with creatinine clearance <60mL/min, consider Raltegravir 400mg PO twice daily, plus Zidovudine and Lamivudine with doses adjusted to the degree of renal dysfunction.[5]
  • If the source exposure does report exposure to HIV within the last 6 weeks, HIV RNA PCR (HIV viral load) should be sent along with HIV Ag/Ab screen on the source and nPEP should be initiated for the exposed patient
    • If both tests result not detected and nonreactive, respectively, nPEP should be discontinued.
    • If the source is willing and able to be tested and is found to be HIV-negative with no recent high-risk exposures to HIV, nPEP is not indicated and should not be initiated, or discontinued if already started.
    • The exposed patient still warrants baseline HIV testing and should be offered baseline and follow-up testing for other transmissible infections, e.g. hepatitis A, B, and C, syphilis, chlamydia, and gonorrhea.

Hepatitis B

  • Not normally indicated, assuming patient has had full course of Hepatitis B vaccination (as all healthcare workers should have)

Hepatitis C

  • No prophylaxis regimen has any benefit

Disposition

  • Outpatient management with employee health follow-up

See Also

References

  1. Fretz R, Negro F, Bruggmann P et al. Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. Swiss Med Wkly. 2013 May 17;143:w13793.
  2. Kuhar D, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. September 2013. 34(9):875-892. DOI: 10.1086/672271. http://www.jstor.org/stable/10.1086/672271
  3. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services
  4. Kuhar DT et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92. doi: 10.1086/672271.
  5. Dominguez KL et al. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV--United States, 2016. Available at: https://stacks.cdc.gov/view/cdc/38856